Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.
Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, Brookes P, de la Fuente J, Kanfer E, Apperley JF, Goldman JM. Craddock C, et al. Among authors: olavarria e. Br J Haematol. 2001 Jan;112(1):228-36. doi: 10.1046/j.1365-2141.2001.02519.x. Br J Haematol. 2001. PMID: 11167809 Free article.
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F, Kaeda J, Cross NC, Craddock C, Kanfer E, Apperley J, Goldman JM. Mughal TI, et al. Among authors: olavarria e. Br J Haematol. 2001 Dec;115(3):569-74. doi: 10.1046/j.1365-2141.2001.03155.x. Br J Haematol. 2001. PMID: 11736937 Free article.
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF. Marin D, et al. Among authors: olavarria e. Leukemia. 2005 Apr;19(4):507-12. doi: 10.1038/sj.leu.2403664. Leukemia. 2005. PMID: 15703781
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F. Simula MP, et al. Among authors: olavarria e. Leukemia. 2007 May;21(5):943-8. doi: 10.1038/sj.leu.2404641. Epub 2007 Mar 15. Leukemia. 2007. PMID: 17361226
150 results